SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Will Biotech Unicorns Soon Be on The Endangered Species List?
The pace of unicorn creation – which is still quite fast – is slowing as economists predict a coming recession. BioSpace sought out the perspective of four experts.
July 12, 2022
 · 
4 min read
 · 
Gail Dutton
GeoVax VP of Business Development/Courtesy of GeoV
Business
Well-Versed Sharkey Ready to Take GeoVax from Buyer to Seller
Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.
July 10, 2022
 · 
5 min read
 · 
Gail Dutton
Researchers Identify Key to Developing Effective Staph Vaccines in Humans
Facing the looming threat of AMR, researchers finally have a new clue as to why attempts to develop an effective S. aureus vaccine have failed. BioSpace spoke with the team leaders.
July 7, 2022
 · 
4 min read
 · 
Gail Dutton
Business
After Layoffs, Big Companies Advance and Small Firms Retrench
After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.
June 30, 2022
 · 
5 min read
 · 
Gail Dutton
Yong Xu/Baylor University, Jonathan Long/Stanford
Exercise in a Pill: Key Molecules Identified that Decrease Hunger Post-Exercise
For the exercise-phobic, a pill that would create the benefits of exercise without the work has been a pipe dream. Today, such a pill – actually, an “anti-hunger molecule” – is a bit closer to reality.
June 27, 2022
 · 
4 min read
 · 
Gail Dutton
Business
Roche Accelerator in Shanghai Helps Biotechs Expand Collaborations & Networks
The Roche Accelerator is designed to help companies bridge the gap between idea and proof-of-concept. It is one of several incubators recently founded by Western companies.
June 23, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
PhaseBio’s Reversal Agent for Astra’s Brilinta could Spell Success for Both
PhaseBio is working toward mitigating the surgical risks for cardiac patients taking antiplatelet therapies with bentracimab, which is currently in Phase III development.
June 22, 2022
 · 
4 min read
 · 
Gail Dutton
TC BioPharm CEO Bryan Kobel/Courtesy of TC BioPhar
Drug Development
TC BioPharm’s Co-Stimulatory CAR Therapy May Be Safer and More Economical
TC BioPharm is developing a new approach to chimeric antibody receptor (CAR) T-cell therapies with the potential to eliminate off-target effects, and possibly help more patients.
June 21, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Diversity Makes Clinical Trial Recruitment Easier and Outcomes Better
Decentralized clinical trials may cost more upfront, but can have huge returns on the back end, according to speakers at Informa Connect’s Decentralized Clinical Trials meeting.
June 21, 2022
 · 
5 min read
 · 
Gail Dutton
Drug Development
Rain Targets Normal p53 Expression with Possible Pan-Cancer Therapeutic
In the coming 12 months, Rain expects to have an interim readout for a Phase II study of its liposarcoma therapy, milademetan, and a pivotal readout for its Phase III trial of the same compound.
June 20, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
CVS Health Banks on Trust to Increase Diversity in Clinical Trials
CVS Health has seen about 40% patient diversity in the work it has done so far, Josh Rose, VP and head of decentralized clinical trials, site solutions and strategy told BioSpace.
June 20, 2022
 · 
5 min read
 · 
Gail Dutton
Michael Vi/Getty Images, Mark Wildgust_Janssen Bio
Drug Development
Janssen Recruiting for Phase III Trials of Potential Myasthenia Gravis Game Changer
BioSpace spoke with Janssen’s Fiona Elwood about the company’s myasthenia gravis candidate nipocalimab, which is currently recruiting for two Phase III trials.
June 18, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Pilot Programs Prepare Decentralized Trials for Prime Time in EU and Japan
Speakers from Sanofi and CMIC discussed their respective experiences with DCT in Europe and Japan during Informa Connect’s Decentralized Clinical Trials hybrid meeting, held June 6-8.
June 16, 2022
 · 
5 min read
 · 
Gail Dutton
Image: The Colon Intestine-Chip: Immune Cell Recru
Drug Development
Emulate Launches Colon Intestine-Chip Assay to Predict Therapeutic Efficacy in IBD
The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.
June 14, 2022
 · 
4 min read
 · 
Gail Dutton
Maria Whitman_ZS Associates
Policy
China Update: Pharma Downplays Challenges, Seeing Innovation Instead
Despite geopolitical tensions, the pharmaceutical industry sees China as a land of opportunity and some largely surmountable challenges.
June 14, 2022
 · 
4 min read
 · 
Gail Dutton
Load More